Preliminary experience with steroidal ovarian suppression for prevention of severe ovarian hyperstimulation syndrome in IVF patients.
The purpose of the study was to evaluate the efficiency of administration of high dose progesterone in combination with oestradiol during the luteal phase for the prevention of ovarian hyperstimulation syndrome in a high-risk population of patients undergoing in vitro fertilization. An observational study was carried out involving 21 women (mean age 28.6 years) undergoing controlled ovarian stimulation for in vitro fertilization. The women were identified as at risk of ovarian hyperstimulation syndrome as they had suffered from the condition when hCG was used for luteal phase support in previous cycles. Steroidal suppression of the stimulated ovary on days 2, 6, 10 and 14 after embryo transfer was achieved by intramuscular injections of 500 mg hydroxyprogesterone caproate and 10 mg oestradiol valerate. The incidence of moderate and severe ovarian hyperstimulation syndrome under steroidal ovarian suppression, serum progesterone concentration and pregnancy rates were compared with those in cycles in which human chorionic gonadotrophin was used for luteal phase support. No cases of moderate or severe ovarian hyperstimulation syndrome occurred under steroidal ovarian suppression. Despite low progesterone concentrations (mean 10.7 nmol l(-1), range 2.6-24.5), indicating almost complete ovarian suppression, the pregnancy rate was not impaired. These preliminary results indicate that steroidal ovarian suppression during the luteal phase is a promising tool for reducing the incidence and severity of ovarian hyperstimulation syndrome in a high-risk population, without compromising the pregnancy rate.
Rjosk
H K
HK
Gemeinschaftspraxis Rjosk/Römmler/Lacher, Westendstrasse 193-195, D-80686 Munich, Germany.
Abendstein
B J
BJ
Kreuzer
E
E
Schwärzler
P
P
D000077713:17 alpha-Hydroxyprogesterone Caproate; D006063:Chorionic Gonadotropin / Q000009:adverse effects; D004624:Embryo Transfer; D004958:Estradiol / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage* / Q000627:therapeutic use; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D007273:Injections, Intramuscular; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control*; D010053:Ovary / Q000187:drug effects*; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D012307:Risk Factors
D006063:Chorionic Gonadotropin; D006908:Hydroxyprogesterones; D000077713:17 alpha-Hydroxyprogesterone Caproate; D011374:Progesterone; D004958:Estradiol